Chronic Kidney Disease (CKD) Market Size, Share, Growth, and Industry Analysis, By Type (Calcium channel blockers, Antihypertensive, Anemia Treatment Drugs, Others) By End Users (Hospital, Clinic) and Regional Insights and Forecast to 2034

•   
•   
  

  Request a Free sample to learn more about this report

    

CHRONIC KIDNEY DISEASE (CKD) MARKET OVERVIEW

The global chronic kidney disease (CKD) market size was USD 0.13 billion in 2025 and is projected to reach USD 0.19 billion by 2034, exhibiting a CAGR of 3.65% during the forecast period.

Chronic kidney disease (CKD) market is an actively developing healthcare segment, which is explained by the growing numbers of people affected by kidney disorders all over the world. CKD is a progressive chronic disorder, which causes, over time, the kidneys to fail, causing cardiovascular diseases, fluid accumulation, anemia, and hypertension, among others. Increased prevalence of diabetes and hypertension, which are the two most common causes of CKD, as well as changes in lifestyle, population aging, and genetic inheritance have played major roles in increasing patient population all over the world. CKD is an emerging public health concern in the world with an estimated prevalence rate of nearly 10 percent of the international population currency (WHO). The therapeutic solutions in the market cover a wider scope that includes antihypertensives, calcium channel blockers, anemia treatment drugs, dialysis, and kidney transplantation therapeutics. Higher awareness, improve diagnostic facilities coupled with the continuing development of pharmaceuticals and biotechnology are changing the scheme of treatment. The government programs to develop better kidney health coupled with increasing R&D expenditure by the drug companies are promoting innovation in the drug formulations and customized treatments. Besides, the trend of implementing telehealth and digital monitoring solutions after COVID-19 has enhanced patient treatment and compliance with treatment regimens. Nevertheless, the treatment is both expensive and inaccessible in many developing economies and its long-term use can come at a cost, as well. Still, it is expected that the CKD market will increase considerably in the next several years because of the pressing need in effective and cheap treatment, partnerships, and use of artificial intelligence in diagnosis. The surface gazes indicate an encouraging growth trend, and the pharmaceutical companies, health care sectors, and governments have critical functions to decrease the load of CKD at the global level.

COVID-19 IMPACT

Chronic Kidney Disease (CKD) Market Had a Negative Effect Due to Supply Chain Disruption During COVID-19 Pandemic

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

The COVID-19 pandemic also affected the chronic kidney disease (CKD) market share significantly and adversely affected the diagnosis, treatment, and patient care. The pandemic has also led to late CKD diagnosis and shifts in the treatment timetables as hospital staff diverted the resources to manage the COVID-19. Patients with CKD are the most vulnerable as they have damaged immune systems, and therefore patients struggled to access healthcare facilities and this means their conditions worsened. There were also shortages in the supply chain of essential medicines such as anti-hypertensives and medicines to treat anemia, which made treatment gaps even more pronounced. With lockdown rules and the fear of getting infections, dialysis centers were visited by fewer patients, and many of them missed periodic sessions. Also, functional clinical trials of new drugs to treat CKD were either postponed or canceled, which lowered the pace of innovation in treatment. Economic Recession also diminished the possibility of patients to access expensive treatment, especially in low and middle countries. During the epidemic, telemedicine alleviated the situation but did not afford similar access to digital healthcare solutions to every patient, and the disparities between patients in receiving treatments increased. The net result includes worse outcomes of patients, a reduction in healthcare costs being spent on non-COVID diseases, and loss of market expansion in 20202021. Although recovery has since started, the pandemic revealed weaknesses in healthcare systems, and the necessity to build resilient CKD management infrastructure.

LATEST TRENDS

Integration of Artificial Intelligence in CKD Management Drives Market Growth

One of the greatest trends affecting the market of chronic kidney disease (CKD) is the growth of the use of artificial intelligence (AI) and digital health in diagnosis, monitoring, and personalized treatment. Artificial intelligence algorithms are being installed to analyze data of the patients, detect early symptoms, and forecast disease development more successfully than conventional diagnostic devices. Mobile health applications and wearable devices allow one to monitor various vital parameters, including blood pressure, blood sugar levels, and kidney functions on an ongoing basis, which makes it possible to implement interventions early. AI is also used to improve drug discovery and management of clinical trials, allowing the fast pacing of new treatment solutions to CKD. As another example, predictive analytics are enabling risk stratification of patients and the differentiation of treatment plans, which lowers the rates of hospitalization and enhances long-term patient outcomes. In addition, digital solutions are filling the communication gaps between the patient and the doctor with the help of teleconsultations which are extremely important during and after the COVID-19 pandemic. Health care providers and pharmaceutical companies are getting more involved in collaborations with health-tech companies to use such inventions. Not only does this trend create efficiency and better patient outcomes, it also helps in bringing healthcare costs down by cutting instances of complications and last-minute emergency intervention. Routine use of AI-based CKD management should transform patient-centered care in the coming years as it will make care more accurate, available, and affordable to patients.

•   
•   
  

  Request a Free sample to learn more about this report

    

CHRONIC KIDNEY DISEASE (CKD) MARKET SEGMENTATION

By Type

Based on type, the global market can be categorized into Calcium channel blockers, Antihypertensive, Anemia Treatment Drugs, Others

• Calcium Channel Blockers: Being prescribed widely to patients with CKD to manage hypertension, calcium channel blockers have a positive effect on the blood vessels by relaxing them and removing the pressure on the kidneys. They also reduce blood pressures and are frequently combined in therapies. They are critical in the retardation of CKD that is associated with hypertension.

• Antihypertensive Drugs: Use of these kinds of drugs in the management of CKD is essential because high blood pressure or hypertension is among the major causes and effects of the kidney damage. They assist in keeping the blood pressure stable, lower proteinuria, and postpone renal failure. ACE inhibitors and ARBs are common ones.

• Anemia Treatment Drugs: Anemia is a common problem of CKD patients since erythropoietin is produced less by kidneys. Agents like erythropoiesis-stimulating agents (ESAs) and iron supplements increase production of red blood cells. Such therapies improve the vitality in patients and their general quality of life.

• Others: This group consists of Diuretic, phosphate binders, and vitamin D Analogs that are used to control the CKD complications. They promote fluid stability, bones health and stable metabolism in patients. Treatment is usually offered where such therapies supplement use of primary drugs.

By End Users

Based on End Users, the global market can be categorized into Hospital, Clinic

• Hospital: Although nowadays CKD is also treated in many other facilities, hospitals continue to be the main centers of CKD treatment, which provide dialysis facilities, latest diagnostic devices, and nephrology care. It includes the highest number of patients and use of drugs.

• Clinic: The clinics will offer outpatient care in the management of CKD stage-1-2, prescription refills and regular examinations. They play a key role in expanding facilities accessible in both urban and semi-urban areas providing care particularly to non-critical cases of CKD.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.

Driving Factors

Rising Prevalence of Diabetes and Hypertension Boost the Market

Growing cases of diabetes and hypertension globally are one of the key growth factors of the chronic kidney disease (CKD) market growth. The two conditions are prime causes of CKD with almost two-thirds of cases of CKD recorded globally being related to them. As people lead sedentary lives, follow inappropriate dietary needs, and obesity rates increase, the population exposed to the risk of damaging their kidneys is also on the rise. The International Diabetes Federation has estimated that by the year 2030, there will be a large number of people globally with diabetes which is close to 640 million implying that CKD incidence will be extremely high. On the same note, the world has more than 1 billion people affected by hypertension although a higher percentage of them are still unknown to the condition or those yet to be treated. Increase in number of patients contributes to both increasing the need of antihypertensive medication, treatment of anemia and dialysis services. Application trends in the health care systems Healthcare systems are giving more weight to CKD screening programs in the at-risk population, which subsequently increases the demand in the diagnostics and the early intervention therapies. Therefore, the increased incidences these chronic diseases pose will guarantee stability and growth in terms of demand in the CKD market.

Growing Advancements in Therapeutics and Diagnostics Expand the Market

Another major factor that has contributed to the CKD industry is technological advancement in drug development, biologics and diagnostic procedures. The application of novel erythropoiesis-stimulating agents, sodium-glucose co-transporter-2 (SGLT2) inhibitors, and precision medicine is changing the CKD management. Moreover, recent developments in the field of biomarkers-based testing and imaging modalities provide the possibility to detect kidney functioning and monitor it early and accurately to implement timely interventions. Clinical trials determine cell-based therapies and gene-editing possibilities to repair kidneys, whereas biopharmaceutical investments in R&D focus on this field. Moreover, Artificial Intelligence-powered platforms that focus on diagnosis and even wearable gadgets are enhancing patient engagement and adherence to treatment. Both of these innovations increase the therapeutic arsenal and meet unmet medical needs to promote positive long-term results. The survival rates of patients and their quality of life in case of adoption of innovative advances in medicine are on the rise. All these developments have added up to a rising confidence in contemporary CKD treatment, which fueled both the growth of the market and an incentive to pursue regular innovation in the industry.

Restraining Factor

High Treatment Costs and Limited Accessibility Potentially Impede Market Growth

A major restraining influence in the chronological kidney disease (CKD) marketplace is the interception of high cost of therapeutics and its low availability in terms of advanced medical amenities. Treatment of renal failure requires dialysis, kidney transplant, and lifetime drugs, which are costly and impose a greater financial burden on the patients, particularly in the low- and middle-income countries. Although in the developed world, partially these costs are covered by the insurance system, in underdeveloped territories, government funds and the lack of healthcare infrastructure present problems. Also, the disproportionate location of dialysis centers and transplant units usually causes the patient to commute long distances in order to receive such treatment regularly. These obstacles lead to late diagnoses, ineffectiveness in following treatments, and increased mortality levels. Therefore, with the increase in the worldwide demand of CKD management, the issue of affordability and accessibility is currently one of the main barriers to market growth. To deal with this challenge, the government has to play a role, and more funding as well as cooperation with the private players are necessary to create viable solutions at a reasonable cost.

Advances in Personalized Medicine and Biopharmaceuticals Create Opportunity for The Product in The Market

Opportunity

The evolution of personalized medicine and the creation of innovative biopharmaceutical treatments is one of the most significant opportunities of the CKD market. The management of CKD is changing through innovations like gene therapy, cell-based therapies and precision drug development. Pharmaceutical companies are now paying more attention to the treatment that is customized according to patient types, which enhances the effects of treatment and minimizes the risks. Besides, artificial intelligence and data analytics are transforming healthcare by helping to predict individual diagnoses, allowing for increased monitoring of patients, earlier intervention, and slower progression of the disease.

There is great potential in biopharmaceuticals treating renal fibrosis, inflammation, and metabolic dysfunction that provide hope to patients that already heavily depend on dialysis or transplantations. These trends are likely to unleash profitable opportunities in the market in view of growing R&D investments and regulatory support in the breakthrough therapies. More than that, the increasing popularity of early screening and the introduction of online health services reinforce this market expansion opportunity.

Late Diagnosis and Poor Patient Compliance Could Be a Potential Challenge for Consumers

Challenge

The major problem in the CKD market is the key issue of low levels of late diagnosis and compliance with treatment plans. CKD may develop without strong signs at the early stages and may leave the patients unaware of its presence until its progression reaches serious conditions. Most patients with the condition end up getting treatment when kidney damage cannot be reversed by that time and this makes managing such conditions more complicated and expensive. Moreover, the adherence of the patients to the prescribed treatments, their diets, and follow-up is also low because of the lack of education, financial burdens, or the inability to visit the specialists.

This failure to comply will help in progression in the disease providing recurring hospital stays and escalating healthcare expenses. The fact that dialysis centers and the transplant waiting lists are overstrained also stresses the importance of dealing with this problem in the healthcare system. To solve this issue, it is essential to introduce better awareness campaigns, screening at early levels, patient education, and the creation of simplified treatment regimens to guarantee the long-term compliance with them.

•   
•   
  Request a Free sample to learn more about this report

    

CHRONIC KIDNEY DISEASE (CKD) MARKET REGIONAL INSIGHTS

• North America

North America especially, the United States chronic kidney disease (CKD) market has the largest share in the market due to well-developed healthcare infrastructure, prevalence of the disease, and considerable investments in research and developments. Due to various underlying factors like diabetes, obesity and hypertension, the incidence of CKD in the region is among the highest, which makes a robust demand towards effective treatment solutions. The existence of major players in the pharmaceutical and biotechnological industry, government friendly policies, all promotes research and development in new treatments and new modes of diagnosis. Also, successfully implemented reimbursement methods, and the extensive availability of dialysis centers and transplant centers would contribute to the better outcomes of patients and stimulate the market growth. The provision of advanced treatments is also increased by the strategic partnerships of the hospitals, research facilities, and privately owned entities. As the number of digital healthcare tools, AI-based diagnostics, and personalized medicine becomes even more environmentally friendly, North America will remain a leader in the world CKD market and will become an example of the industry approaches to treatment.

• Europe

Europe is a powerful regional market in CKD, as it is helped by highly developed medical research, government health care schemes, and the rising awareness of early detection of kidney disease. The area has the availability of universal health systems in most of the countries that guarantee availability of dialysis, transplants, and drugs at a subsidized price. Europe is also dominating clinical trials and regulatory permissions with the European medicines Agency (EMA) which promotes innovations with new medicines. The increase in the incidence of lifestyle related illnesses, e.g., obesity and diabetes, is also leading to the prevalence of CKD and forming a great demand of treatment options. Moreover, Europe also pays significant attention to the preventive medicine and health promotion efforts, which can postpone the progression of the condition and set a system of regular check-ups. The contribution of large pharmaceutical companies and manufacturers of healthcare technologies contributes to the ability of the region to lead the changes in treatment. Europe is projected to continue playing an important role in the global CKD market as healthcare goes digital.

• Asia

Asian market is proving to be a rapidly developing market in terms of CKD due to the high number of people, the increasing rates of diabetes and hypertension, and the fact that the healthcare infrastructure is also improving. There is an increase in the number of CKD patients in countries like China, India, and Japan that is pushing towards the extensive need of dialysis centers, transplant units, and low-cost drugs. Although the cost issue is persisting, governments in the region have started to invest in healthcare reforms and increase the insurance cover to enhance patient accessibility. Also, international firms are joining hands with local players in developing manufacturing units and distribution channels thus easing the access to more specialized treatments at cheaper rates. There is also the enhanced management of the diseases, particularly in rural regions that telemedicine and digital health solutions are easing. As the emphasis has shifted towards awareness raising programs and the earlier screenings, Asia is assumed to become an increasingly significant factor in the global CKD market in the next few years.

KEY INDUSTRY PLAYERS

Key Industry Players Shaping the Market Through Innovation and Market Expansion

The main players in the chronic kidney disease (CKD) market are influencing the current shape of the market, actively promoting the increase in the level of treatment, diagnostics, and patient management. Some of the companies leading in the field of developing therapy focusing on CKD progression and its comorbidities include AbbVie Inc. (USA), AstraZeneca plc (UK), Johnson & Johnson (USA), Bayer AG (Germany), GlaxoSmithKline plc (UK), and Novartis AG (Switzerland). AbbVie is an important player in drugs with a focus on slowing CKD progression and AstraZeneca is progressing to produce SGLT2 inhibitors such as Farxiga which is demonstrating some benefits to CKD patients. Johnson & Johnson and Bayer are focusing on the development of new cardiovascular-renal treatment to deal with problems due to CKD. Moreover, it is observed that there are certain companies like the Fresenius Medical Care based in Germany or DaVita Inc. based in the USA, whose core operations are in the diagnostic and dialysis business servicing millions of patients across the globe. New treatment methods based on addressing the unmet medical need in CKD are being presented by biotech companies such as Reata Pharmaceuticals (USA) and Otsuka Pharmaceutical (Japan). Collectively, these competitors in the field are opening up access, gaining operating momentum in research and development, and changing marketplace dynamics via tie-ups, acquisitions and regulatory clearances.

List Of Top Chronic Kidney Disease (Ckd) Companies

• Roche (Switzerland)
• Pfizer (U.S.)
• Teva (Israel)
• AstraZeneca (U.K.)

KEY INDUSTRY DEVELOPMENT

May 2024: AstraZeneca (UK) announced new positive Phase III trial results for its drug Farxiga (dapagliflozin), demonstrating significant benefits in reducing the risk of CKD progression and cardiovascular complications. This development strengthens its market position as a leading therapy for CKD patients beyond diabetes management.

REPORT COVERAGE

Chronic kidney (CKD) disease market is undergoing a swift expansion, as the cases of diabetes, hypertension, and aging worldwide are on the increase, which are key risk factors of CKD. As experts estimate that over 800 million individuals across the globe have some form of CKD, there is an acute need to find new ways of treating it, more sophisticated diagnostic instruments and increased access to kidney care. The Abbey, AstraZeneca, Fresenius Medical Care and Da Vita are leading market players in promoting pharmaceutical and dialysis solutions. Nonetheless, the high prices of treatment, late diagnoses, and scarcity of kidney transplants are other major issues, which deter the adoption of advanced therapies in the wider population. The available opportunities lie in the domains of expanding precision medicine, using AI to early detection, and promoting the number of people who undergo home-based dialysis. The North American region is driven by the development of healthcare to offer better management of CKD in Europe led by policies and the growing numbers of patients in Asia and the subsequent rise in investments in healthcare infrastructure. On the whole, the CKD market is evolving toward more patient-centric and integrated approaches where the cooperation among pharmaceutical organizations, medical devices companies and healthcare facilities will play a crucial role in the decrease of the burden and the better patient survival rates.